

Recombinant Protein Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)

Market Report | 2026-05-20 | 350 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$4949.00
- Five User License \$5949.00
- Corporate License \$6969.00

Report description:

The recombinant protein market was valued at USD 2.11 Billion in 2025 . It is poised to grow at a CAGR of 11.21% during the forecast period of 2026-2035, and reach USD 6.11 Billion by 2035 . The market growth is driven by increasing demand for biologics, rising prevalence of chronic diseases, advancements in expression system technologies, and expanding applications of therapeutic proteins globally.

Key Market Trends and Insights

- By product, the growth factors and cytokines segment held the largest share of over 24% of the market in the historical period.
- By application, the therapeutics segment dominated the global market with a share of above 34.2% in the historical period.
- North America dominated the market with a share of more than 41.1% in the historical period.

Market Size and Forecast

- Market Size (2025): USD 2.11 Billion
- Projected Market Size (2035): USD 6.11 Billion
- CAGR (2026-2035): 11.21%

Recombinant Protein Market Overview

The market is driven by the expanding demand for biologics and advanced therapeutics. The increasing use of expression system platforms such as CHO cell, E. coli expression, baculovirus, and yeast expression is enhancing production efficiency. Rising applications in therapeutic protein development, enzyme production, cytokine, and growth factor recombinant therapies are further supporting steady market growth globally. The market reached a value of approximately USD 2.11 Billion in 2025 .

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Recombinant Protein Market Growth Drivers

Increasing Policy Reforms Supporting the Market Expansion

Growing healthcare cost pressures and increasing biologics demand are driving policy reforms in recombinant protein therapeutics. For instance, in October 2025, the FDA introduced new regulatory guidelines enabling biosimilars to rely more on analytical similarity data rather than large-scale clinical trials. This initiative is reducing development barriers and supporting faster commercialization of recombinant protein-based therapies in oncology and autoimmune disorders.

Recombinant Protein Market Trends

Key trends shaping the market include rising biologics demand, advancements in expression systems, increasing monoclonal antibody production, and expanding therapeutic protein applications globally.

Growing Regulatory Acceleration Driving the Market Demand

Rising regulatory modernization and increasing demand for cost-effective biologics are reshaping recombinant protein market dynamics globally. For instance, in October 2025, the U.S. Food and Drug Administration streamlined biosimilar approval pathways by reducing clinical trial requirements for biologics. This development is accelerating recombinant protein accessibility and improving market entry speed for advanced biologic therapies across multiple disease areas.

Recombinant Protein Market Segmentation

Market Breakup by Product Type

- Growth Factor and Cytokines
- Hormone
- Enzyme
- Antibody
- Immune Checkpoint Proteins
- Recombinant Regulatory Proteins
- Others

Market Breakup by Application

- Therapeutic
- Research
- Biotechnology Industry

Market Breakup by Region

- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Recombinant Protein Market Share

Therapeutics Expected to Lead the Market Segment by Application

The therapeutics segment continues to dominate the market, driven by rising demand for biologics and targeted treatments. During the historical period, it accounted for over 34.2% share, supported by expanding clinical applications and drug development pipelines. Increasing adoption of therapeutic protein solutions is enhancing treatment precision and strengthening market growth across chronic and complex diseases globally.

Recombinant Protein Market Analysis by Region

North America is expected to dominate the market with a share of more than 41% in the historical period. Strong biopharmaceutical infrastructure, advanced R&D capabilities, and high biologics adoption continue to support regional leadership. Growing use of expression system technologies in large-scale protein production further reinforces North America's position as a key hub for recombinant protein innovation and commercialization.

Leading Players in the Recombinant Protein Market

The key features of the market report comprise patent analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Abcam PLC

Abcam PLC, headquartered in Cambridge, United Kingdom, was founded in 1998. The company specializes in protein research tools including antibodies, proteins, peptides, knockout cell lines, lysates, and imaging reagents. Its portfolio supports expression system research workflows, enabling advanced biological studies and accelerating drug discovery and translational research applications globally.

Thermo Fisher Scientific, Inc.

Thermo Fisher Scientific, Inc., headquartered in Waltham, Massachusetts, United States, was established in 2006 through a merger. The company offers analytical instruments, lab services, diagnostics, and life science solutions. Its recombinant protein capabilities support CHO cell-based production platforms, enabling scalable biologics manufacturing and advanced research across pharmaceutical and biotechnology sectors.

Bio-Techne Corporation

Bio-Techne Corporation, headquartered in Minneapolis, Minnesota, United States, was founded in 1976. The company provides proteins, antibodies, enzymes, and cell culture reagents. Its portfolio supports E. coli expression systems for recombinant protein production, enabling high-quality biologics development and accelerating research in immunology, oncology, and regenerative medicine applications.

F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd., headquartered in Basel, Switzerland, was founded in 1896. The company operates in oncology, immunology, infectious diseases, and diagnostics. Its recombinant protein pipeline leverages therapeutic protein development

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

platforms, supporting biologics innovation and advancing targeted therapies for complex and chronic disease management worldwide.

Other key players in the market are Merck KGaA, Bio-Rad Laboratories, Inc., GeneTex, Inc, Lonza Group SA, PerkinElmer Inc., Sino Biological Inc., TAKARA HOLDINGS INC., Tosoh Corporation, XENOTECH AI Pvt Ltd., NEW ENGLAND BIOLABS, INC., and Abbott.

Key Questions Answered in the Recombinant Protein Market Report

- What was the recombinant protein market value in 2025?
- What is the recombinant protein market forecast outlook for 2026-2035?
- What major factors aid the demand for recombinant protein market?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major recombinant protein market trends?
- Which product type is expected to dominate the market segment?
- Which application is expected to dominate the market segment?
- Who are the key players in the recombinant protein market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Recombinant Protein Market Overview
 - 3.1 Global Recombinant Protein Market Historical Value (2019-2025)
 - 3.2 Global Recombinant Protein Market Forecast Value (2026-2035)
- 4 Vendor Positioning Analysis
 - 4.1 Key Vendors
 - 4.2 Prospective Leaders
 - 4.3 Niche Leaders
 - 4.4 Disruptors
- 5 Global Recombinant Protein Market Landscape*
 - 5.1 Global Recombinant Protein: Developers Landscape
 - 5.1.1 Analysis by Year of Establishment
 - 5.1.2 Analysis by Company Size
 - 5.1.3 Analysis by Region
 - 5.2 Global Recombinant Protein: Product Landscape
 - 5.2.1 Analysis by Product
 - 5.2.2 Analysis by Vector
 - 5.2.3 Analysis Application
 - 5.2.4 Analysis by Cell type

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6 Global Recombinant Protein Market Dynamics
 - 6.1 Market Drivers and Constraints
 - 6.2 SWOT Analysis
 - 6.2.1 Strengths
 - 6.2.2 Weaknesses
 - 6.2.3 Opportunities
 - 6.2.4 Threats
 - 6.3 PESTEL Analysis
 - 6.3.1 Political
 - 6.3.2 Economic
 - 6.3.3 Social
 - 6.3.4 Technological
 - 6.3.5 Legal
 - 6.3.6 Environment
 - 6.4 Porter's Five Forces Model
 - 6.4.1 Bargaining Power of Suppliers
 - 6.4.2 Bargaining Power of Buyers
 - 6.4.3 Threat of New Entrants
 - 6.4.4 Threat of Substitutes
 - 6.4.5 Degree of Rivalry
 - 6.5 Key Demand Indicators
 - 6.6 Key Price Indicators
 - 6.7 Industry Events, Initiatives, and Trends
 - 6.8 Value Chain Analysis
- 7 Global Recombinant Protein Market Segmentation (219-2035)
 - 7.1 Global Recombinant Protein Market (2019-2035) by Product Type
 - 7.1.1 Market Overview
 - 7.1.2 Growth Factor and Cytokines
 - 7.1.3 Hormone
 - 7.1.4 Enzyme
 - 7.1.5 Antibody
 - 7.1.6 Immune Checkpoint Proteins
 - 7.1.7 Recombinant Regulatory Proteins
 - 7.1.8 Others
 - 7.2 Global Recombinant Protein Market (2019-2035) by Application
 - 7.2.1 Market Overview
 - 7.2.2 Therapeutic
 - 7.2.3 Research
 - 7.2.4 Biotechnology Industry
 - 7.3 Global Recombinant Protein Market (2019-2035) by Region
 - 7.3.1 Market Overview
 - 7.3.2 North America
 - 7.3.3 Europe
 - 7.3.4 Asia Pacific
 - 7.3.5 Latin America
 - 7.3.6 Middle East and Africa
- 8 North America Recombinant Protein Market (219-2035)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.1 North America Recombinant Protein Market (2019-2035) by Product Type
 - 8.1.1 Market Overview
 - 8.1.2 Growth Factor and Cytokines
 - 8.1.3 Hormone
 - 8.1.4 Enzyme
 - 8.1.5 Antibody
 - 8.1.6 Immune Checkpoint Proteins
 - 8.1.7 Recombinant Regulatory Proteins
 - 8.1.8 Others
- 8.2 North America Recombinant Protein Market (2019-2035) by Application
 - 8.2.1 Market Overview
 - 8.2.2 Therapeutic
 - 8.2.3 Research
 - 8.2.4 Biotechnology Industry
- 8.3 North America Recombinant Protein Market (2019-2035) by Country
 - 8.3.1 United States of America
 - 8.3.2 Canada
- 9 Europe Recombinant Protein Market (2019-2035)
 - 9.1 Europe Recombinant Protein Market (2019-2035) by Product Type
 - 9.1.1 Market Overview
 - 9.1.2 Growth Factor and Cytokines
 - 9.1.3 Hormone
 - 9.1.4 Enzyme
 - 9.1.5 Antibody
 - 9.1.6 Immune Checkpoint Proteins
 - 9.1.7 Recombinant Regulatory Proteins
 - 9.1.8 Others
 - 9.2 Europe Recombinant Protein Market (2019-2035) by Application
 - 9.2.1 Market Overview
 - 9.2.2 Therapeutic
 - 9.2.3 Research
 - 9.2.4 Biotechnology Industry
 - 9.3 Europe Recombinant Protein Market (2019-2035) by Country
 - 9.3.1 United Kingdom
 - 9.3.2 Germany
 - 9.3.3 France
 - 9.3.4 Italy
 - 9.3.5 Others
- 10 Asia Pacific Recombinant Protein Market (2019-2035)
 - 10.1 Asia Pacific Recombinant Protein Market (2019-2035) by Product Type
 - 10.1.1 Market Overview
 - 10.1.2 Growth Factor and Cytokines
 - 10.1.3 Hormone
 - 10.1.4 Enzyme
 - 10.1.5 Antibody
 - 10.1.6 Immune Checkpoint Proteins
 - 10.1.7 Recombinant Regulatory Proteins

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.1.8 Others
- 10.2 Asia Pacific Recombinant Protein Market (2019-2035) by Application
 - 10.2.1 Market Overview
 - 10.2.2 Therapeutic
 - 10.2.3 Research
 - 10.2.4 Biotechnology Industry
- 10.3 Asia Pacific Recombinant Protein Market (2019-2035) by Country
 - 10.3.1 China
 - 10.3.2 Japan
 - 10.3.3 India
 - 10.3.4 ASEAN
 - 10.3.5 Australia
 - 10.3.6 Others
- 11 Latin America Recombinant Protein Market (2019-2035)
 - 11.1 Latin America Recombinant Protein Market (2019-2035) by Product Type
 - 11.1.1 Market Overview
 - 11.1.2 Growth Factor and Cytokines
 - 11.1.3 Hormone
 - 11.1.4 Enzyme
 - 11.1.5 Antibody
 - 11.1.6 Immune Checkpoint Proteins
 - 11.1.7 Recombinant Regulatory Proteins
 - 11.1.8 Others
 - 11.2 Latin America Recombinant Protein Market (2019-2035) by Application
 - 11.2.1 Market Overview
 - 11.2.2 Therapeutic
 - 11.2.3 Research
 - 11.2.4 Biotechnology Industry
 - 11.3 Latin America Recombinant Protein Market (2019-2035) by Country
 - 11.3.1 Brazil
 - 11.3.2 Argentina
 - 11.3.3 Mexico
 - 11.3.4 Others
- 12 Middle East and Africa Recombinant Protein Market (2019-2035)
 - 12.1 Middle East and Africa Recombinant Protein Market (2019-2035) by Product Type
 - 12.1.1 Market Overview
 - 12.1.2 Growth Factor and Cytokines
 - 12.1.3 Hormone
 - 12.1.4 Enzyme
 - 12.1.5 Antibody
 - 12.1.6 Immune Checkpoint Proteins
 - 12.1.7 Recombinant Regulatory Proteins
 - 12.1.8 Others
 - 12.2 Middle East and Africa Recombinant Protein Market (2019-2035) by Application
 - 12.2.1 Market Overview
 - 12.2.2 Therapeutic
 - 12.2.3 Research

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.2.4 Biotechnology Industry
- 12.3 Middle East and Africa Recombinant Protein Market (2019-2035) by Country
 - 12.3.1 Saudi Arabia
 - 12.3.2 United Arab Emirates
 - 12.3.3 Nigeria
 - 12.3.4 South Africa
 - 12.3.5 Others
- 13 Regulatory Framework
 - 13.1 Regulatory Overview
 - 13.2 US FDA
 - 13.3 EU EMA
 - 13.4 INDIA CDSCO
 - 13.5 JAPAN PMDA
 - 13.6 Others
- 14 Patent Analysis
 - 14.1 Analysis by Type of Patent
 - 14.2 Analysis by Publication Year
 - 14.3 Analysis by Issuing Authority
 - 14.4 Analysis by Patent Age
 - 14.5 Analysis by CPC Analysis
 - 14.6 Analysis by Patent Valuation
 - 14.7 Analysis by Key Players
- 15 Clinical Trial Analysis
 - 15.1 Analysis by Trial Registration Year
 - 15.2 Analysis by Trial Status
 - 15.3 Analysis by Trial Phase
 - 15.4 Analysis by Therapeutic Area
 - 15.5 Analysis by Geography
- 16 Grant Analysis
 - 16.1 Analysis by Year
 - 16.2 Analysis by Amount Awarded
 - 16.3 Analysis by Issuing Authority
 - 16.4 Analysis by Grant Product
 - 16.5 Analysis by Funding Institute
 - 16.6 Analysis by Departments
 - 16.7 Analysis by Recipient Organization
- 17 Funding and Investment Analysis
 - 17.1 Analysis by Funding Instances
 - 17.2 Analysis by Type of Funding
 - 17.3 Analysis by Funding Amount
 - 17.4 Analysis by Leading Players
 - 17.5 Analysis by Leading Investors
 - 17.6 Analysis by Geography
- 18 Strategic Initiative
 - 18.1 Analysis by Partnership Instances
 - 18.2 Analysis by Type of Partnership
 - 18.3 Analysis by Leading Players

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 18.4 Analysis by Geography
- 19 Supplier Landscape
- 19.1 Market Share Analysis, By Region (Top 5 Companies)
 - 19.1.1 Market Share Analysis: Global
 - 19.1.2 Market Share Analysis: North America
 - 19.1.3 Market Share Analysis: Europe
 - 19.1.4 Market Share Analysis: Asia-Pacific
 - 19.1.5 Market Share Analysis: Others
- 19.2 Abbott
 - 19.2.1 Financial Analysis
 - 19.2.2 Product Portfolio
 - 19.2.3 Demographic Reach and Achievements
 - 19.2.4 Mergers and Acquisitions
 - 19.2.5 Certifications
- 19.3 Abcam PLC
 - 19.3.1 Financial Analysis
 - 19.3.2 Product Portfolio
 - 19.3.3 Demographic Reach and Achievements
 - 19.3.4 Mergers and Acquisitions
 - 19.3.5 Certifications
- 19.4 Thermo Fisher Scientific, Inc.
 - 19.4.1 Financial Analysis
 - 19.4.2 Product Portfolio
 - 19.4.3 Demographic Reach and Achievements
 - 19.4.4 Mergers and Acquisitions
 - 19.4.5 Certifications
- 19.5 Bio-Techne Corp.
 - 19.5.1 Financial Analysis
 - 19.5.2 Product Portfolio
 - 19.5.3 Demographic Reach and Achievements
 - 19.5.4 Mergers and Acquisitions
 - 19.5.5 Certifications
- 19.6 Merck KGaA
 - 19.6.1 Financial Analysis
 - 19.6.2 Product Portfolio
 - 19.6.3 Demographic Reach and Achievements
 - 19.6.4 Mergers and Acquisitions
 - 19.6.5 Certifications
- 19.7 Bio-Rad Laboratories, Inc.
 - 19.7.1 Financial Analysis
 - 19.7.2 Product Portfolio
 - 19.7.3 Demographic Reach and Achievements
 - 19.7.4 Mergers and Acquisitions
 - 19.7.5 Certifications
- 19.8 GeneTex, Inc
 - 19.8.1 Financial Analysis
 - 19.8.2 Product Portfolio

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 19.8.3 Demographic Reach and Achievements
- 19.8.4 Mergers and Acquisitions
- 19.8.5 Certifications
- 19.9 Lonza Group SA
 - 19.9.1 Financial Analysis
 - 19.9.2 Product Portfolio
 - 19.9.3 Demographic Reach and Achievements
 - 19.9.4 Mergers and Acquisitions
 - 19.9.5 Certifications
- 19.10 F. Hoffmann-La Roche Ltd.
 - 19.10.1 Financial Analysis
 - 19.10.2 Product Portfolio
 - 19.10.3 Demographic Reach and Achievements
 - 19.10.4 Mergers and Acquisitions
 - 19.10.5 Certifications
- 19.11 PerkinElmer Inc.
 - 19.11.1 Financial Analysis
 - 19.11.2 Product Portfolio
 - 19.11.3 Demographic
 - 19.11.4 Mergers and Acquisitions
 - 19.11.5 Certifications
- 19.12 Sino Biological Inc.
 - 19.12.1 Financial Analysis
 - 19.12.2 Product Portfolio
 - 19.12.3 Demographic Reach and Achievements
 - 19.12.4 Mergers and Acquisitions
 - 19.12.5 Certifications
- 19.13 TAKARA HOLDINGS INC.
 - 19.13.1 Financial Analysis
 - 19.13.2 Product Portfolio
 - 19.13.3 Demographic Reach and Achievements
 - 19.13.4 Mergers and Acquisitions
 - 19.13.5 Certifications
- 19.14 Tosoh Corporation
 - 19.14.1 Financial Analysis
 - 19.14.2 Product Portfolio
 - 19.14.3 Demographic Reach and Achievements
 - 19.14.4 Mergers and Acquisitions
 - 19.14.5 Certifications
- 19.15 XENOTECH AI Pvt Ltd.
 - 19.15.1 Financial Analysis
 - 19.15.2 Product Portfolio
 - 19.15.3 Demographic Reach and Achievements
 - 19.15.4 Mergers and Acquisitions
 - 19.15.5 Certifications
- 19.16 NEW ENGLAND BIOLABS, INC
 - 19.16.1 Financial Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

19.16.2 Product Portfolio
19.16.3 Demographic Reach and Achievements
19.16.4 Mergers and Acquisitions
19.16.5 Certifications
20 Recombinant Protein Market - Distribution Model (Additional Insight)
20.1 Overview
20.2 Potential Distributors
20.3 Key Parameters for Distribution Partner Assessment
21 Key Opinion Leaders (KOL) Insights (Additional Insight)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Recombinant Protein Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)

Market Report | 2026-05-20 | 350 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4949.00
	Five User License	\$5949.00
	Corporate License	\$6969.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-06-08"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

